A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist ODM-201
Phase of Trial: Phase 0
Latest Information Update: 07 Oct 2017
At a glance
- Drugs Darolutamide (Primary)
- Indications Breast cancer
- Focus Pharmacodynamics
- 03 Aug 2017 Status changed from not yet recruiting to recruiting.
- 13 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
- 26 Jun 2017 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.